Singapore, Aug 30, 2010: BioTime, headquartered in California, a biotechnology company focused on regenerative medicine and blood plasma volume expanders, has announced that it will launch seven new human embryonic progenitor cell lines and seven novel culture media for these lines on September 1, 2010. These progenitor lines were produced from embryonic stem cells using the company's ACTCellerate technology.

Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and fully differentiated cells. The cells may possess the ability to become a wide array of cell types with potential applications in research, drug discovery, and potential novel regenerative stem cell therapies. The cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of human embryonic stem cells.

Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications.